Search

Search Constraints

You searched for: Author/Creator Badange, Rajesh Kumar

Search Results

1. 0265 Samelisant (SUVN-G3031), a Histamine H3 Receptor Inverse Agonist in Animal Models of Narcolepsy. (25th May 2022)

2. 1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6, 7‐dihydro‐4H‐thiazolo[5, 4‐c]pyridin‐5‐yl]propan‐1‐one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition. (18th November 2021)

3. [P1–079]: SUVN‐I6107: A NOVEL MUSCARINIC M1 RECEPTOR‐POSITIVE ALLOSTERIC MODULATOR (M1‐PAM) DEVOID OF CHOLINERGIC SIDE EFFECTS. (1st July 2017)

4. Effect of Concurrent Use of Memantine on The Efficacy of Masupirdine (SUVN‐502): A Post‐hoc Analysis of a Phase‐2 Randomized Placebo‐Controlled Study. (20th December 2022)

5. Effects of Masupirdine (SUVN‐502) on Agitation/Aggression and Psychosis in Patients with Probable Alzheimer's Disease: A Post Hoc Analysis. (20th December 2022)

6. Masupirdine (SUVN‐502) in combination with donepezil and memantine in moderate Alzheimer's disease: Effect of AD duration since diagnosis and patient's age on efficacy endpoints: Human/Human trials: Cognitive enhancement. (7th December 2020)

7. P1‐310: Suvn‐g3031, an h3 receptor inverse agonist, produces procognitive effects without affecting sleep in preclinical models. (1st July 2015)

8. P2‐031: SAFETY, TOLERABILITY AND HUMAN PHARMACOKINETICS OF SUVN‐502, A POTENT AND PURE 5‐HT6 RECEPTOR ANTAGONIST. (1st July 2019)

9. P3‐296: Safety, tolerability, and pharmacokinetics of a potent and selective 5‐ht6 receptor antagonist, SUVN‐502, following multiple ascending doses in healthy elderly subjects, and effect of gender and food on single‐dose pharmacokinetics. (1st July 2015)

10. P3‐390: EFFECT OF GENDER AND FOOD ON THE SINGLE‐DOSE PHARMACOKINETICS OF SUVN‐502, A POTENT AND SELECTIVE 5‐HT6 RECEPTOR ANTAGONIST. (1st July 2014)